Skip to main content

Conference Correspondent

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="23" name="CC Event Nav"]
Resistance to the combination of osimertinib plus savolitinib is predominantly mediated by acquired mutations in either MET, EGFR, or KRAS in patients with EGFR-mutated metastatic non–small-cell lung cancer (NSCLC). Read More ›

Based on results of the RATIONALE 303 trial, tislelizumab significantly prolonged median overall survival by more than 5 months in patients with advanced non–small-cell lung cancer (NSCLC) compared with docetaxel. Read More ›

Compared with docetaxel, sintilimab significantly prolonged median overall survival by more than 3 months in patients with advanced squamous non–small-cell lung cancer (NSCLC). Read More ›

In patients with advanced squamous non–small-cell lung cancer (NSCLC), the combination of bintrafusp alfa and chemotherapy was well tolerated. The most common treatment-related adverse events were anemia, nausea, and pruritus. Read More ›

Combining nivolumab with a limited course of chemotherapy in resectable non–small-cell lung cancer (NSCLC) enhances rates of pathologic complete response compared with chemotherapy alone. Read More ›

Findings of the prospective community-based observational NILE study support the use of cfDNA to identify actionable genomic alterations in newly diagnosed patients with advanced lung adenocarcinoma. Read More ›

Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing. Read More ›

The LC-SCRUM-Asia project analysis indicated that utilization of rapid multigene assays in patients with advanced non–small-cell lung cancer (NSCLC) was associated with short turnaround times and high success rates compared with a targeted assay. Read More ›

Provider adherence to National Comprehensive Cancer Network recommendations and implementation of an automated regimen-level prior authorization is associated with lower cost and more efficient oncology care in patients with non–small-cell lung cancer. Read More ›

The majority of progressing stage IV non–small-cell lung cancer patients with development of resistance to targeted therapies benefit from repeat molecular profiling to detect actionable resistance mechanisms and facilitate clinical trial enrollment. Read More ›

Page 9 of 27